CHENGDU,
China, Nov. 29, 2024 /PRNewswire/ -- BGM Group
Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global
pharmaceutical enterprise, today announced its acquisition of the
intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at
1 billion RMB (approximately
$140 million). The intelligent
platform encompasses AIX's subsidiaries – RONS Intelligent
Technology (Beijing) Co., Ltd.
("RONS Technology") and Shenzhen Xinbao Investment Management Co.,
Ltd. ("Xinbao Investment"). Completion of the transaction is
anticipated by the end of 2024.
Through this strategic acquisition, BGM formally ventures into
the domains of AI intelligent technology and financial and
insurance services, setting the stage for diversified growth beyond
biopharmaceuticals and inaugurating a new era for the Company in
the digital and intelligent landscape.
Mr. Xin Chen, CEO of BGM,
commented, "AIX's efforts in digital innovation and intelligent
transformation have yielded remarkable outcomes. Their accumulated
technology and expertise will serve as a crucial reference for our
own transformation in the pharmaceutical and healthcare sectors.
This collaboration will not only bolster BGM's technological
capabilities but also expedite our strategic development, enabling
us to deliver more efficient and intelligent solutions to the
global market. This partnership represents a mutually beneficial
opportunity and I am optimistic about our future together."
Mr. Hu Yinan, CEO of AIX, stated, "Intelligent technology is the
future of the insurance sector. AIX's intelligent platform has
already exhibited significant potential within the industry.
However, broader advancement requires an open industry perspective
and ecological support. Partnering with BGM will allow our platform
to reach a wider user base and unlock greater potential for AI
technology beyond the insurance realm. Furthermore, this
collaboration aligns with national elderly care policies and
promotes the growth of the silver economy. By extending our
intelligent capabilities from insurance into the pharmaceutical and
healthcare sectors, we aim to facilitate industry transformation
through technology and propel AIX's growth. AIX will maintain its
role as the primary user of the intelligent platform, actively
investing resources to maximize its technological capabilities. We
are confident that this collaboration will create new opportunities
for both AIX and the intelligent platform, enhancing value for our
customers, industry partners, and shareholders."
Founded in 2009, RONS Technology, a wholly-owned subsidiary
of AIX, specializes in developing digital and intelligent
technologies for the financial and insurance industries. RONS
Technology boasts extensive experience in insurtech, having
introduced disruptive innovations through its RONS Open Platform
and flagship product Du Xiaobao. RONS Technology has steadily built
a strong presence within the insurtech landscape, offering
substantial growth potential and development opportunities.
Established in 2004, Xinbao Investment has developed a
professional integrated online and offline insurance trading and
service platform known as "Baowang". Baowang provides comprehensive
risk protection solutions for individuals, families, and small to
medium-sized enterprises through the integration of technology,
products, and services. The platform currently offers over 300
flagship products from more than 30 insurance companies, addressing
various protection needs such as critical illness, term life,
accident, health, travel, and corporate insurance.
By acquiring RONS Technology and Xinbao Investment, BGM will
effectively integrate resources from intelligent technology and
biopharmaceuticals, creating a new landscape for the synchronized
development of "healthcare, medicine, and insurance" in the global
market. The technological innovations from RONS Technology,
particularly the pioneering achievements of Du Xiaobao in insurance
sales, will empower BGM to strengthen its competitive advantage at
the intersection of medical technology and insurance technology,
offering users comprehensive and intelligent healthcare and
insurance solutions while further expanding its global
influence.
Moreover, RONS Technology and Xinbao Investment will benefit
from enhanced development opportunities arising from this
transaction. BGM's robust presence in the healthcare sector,
especially its extensive footprint in the global pharmaceutical
market, will provide additional application scenarios for the
products and services of both entities. RONS Technology and Xinbao
Investment intend to leverage BGM's international market network
and pharmaceutical expertise to explore novel development models
within the healthcare and insurance industries, continuously
broaden their market reach, and serve as potent profit generators
for BGM in the future.
About BGM Group Ltd
BGM Group Ltd,headquartered in Chengdu, China, is an innovative company dedicated to
the fields of biopharmaceuticals, bio-extraction, and medical
health. Our current product range includes oxytetracycline APIs,
licorice preparations, and crude heparin sodium. The
oxytetracycline API not only provides raw materials for
pharmaceutical companies to produce human antibiotics but also
supports the global breeding and livestock industries to ensure the
safety of poultry and seafood. The crude heparin sodium, after
processing by downstream companies, is transformed into refined
heparin sodium and heparin sodium injection solutions, which are
major anticoagulants. Licorice preparations, such as compound
licorice lozenges, are used as cough suppressants and supplied to
retail pharmacies. For more information, visit the Company's
website at: https://www.bgmgroupltd.com/
Forward-looking Statements
This news release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will", "expects", "anticipates",
"future", "intends", "plans", "believes", "estimates", "target",
"going forward", "outlook" and similar statements. Such statements
are based upon management's current expectations and current market
and operating conditions and relate to events that involve known or
unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond the Company's
control, which may cause the Company's actual results, performance
or achievements to differ materially from those in the
forward-looking statements. Further information regarding these and
other risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. The
Company does not undertake any obligation to update any
forward-looking statement as a result of new information, future
events or otherwise, except as required under law.
For investor and media inquiries, please contact:
info@qiliancorp.com
xinchen@qiliancorp.com
View original
content:https://www.prnewswire.com/news-releases/bgm-group-ltd-pioneers-innovation-in-ai-and-intel-technology-fostering-holistic-integration-of-healthcare-and-insurtech-302318792.html
SOURCE BGM Group Ltd
